FrancophonIA/ELRC3.0 huggingface dataset:
English: Iron oxide red (E172) Iron oxide black (E172)
Danish: Jernoxid, rød (E172)
English: (-5.9% to
Danish: (-5,9 % til til 1,8 %)
English: • wind (flatulence)
Danish: • afgang af tarmluft (flatulens)
English: HIV-1 isolates with reduced susceptibility to tenofovir alafenamide have been selected in cell culture and had the K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.
Danish: Hiv 1-isolater med reduceret følsomhed over for tenofoviralafenamid er blevet selekteret i cellekultur og havde K65R-mutationen i hiv 1-RT; desuden blev der forbigående observeret en K70E-mutation i hiv 1-RT. Hiv 1-isolater med K65R-mutationen har en lav grad af nedsat følsomhed over for abacavir, emtricitabin, tenofovir og lamivudin.
English: Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Danish: Ætiologien anses dog for at være multifaktoriel (anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, højere Body
English: (Induction of CYP3A, UGT1A1, and P-gp)
Danish: (Induktion af CYP3A, UGT1A1, og P-gp)
English: If you feel dizzy when taking Biktarvy, do not drive and do not use any tools or machines.
Danish: Kør ikke motorkøretøj, og lad være med at arbejde med værktøj eller maskiner, hvis De bliver svimmel, når De tager Biktarvy.
English: Mean percent change in AUC,
Danish: Gennemsnitlig ændring (%) i AUC, Cmax, Cmin
English: Osteonecrosis
Danish: Nefrotoksicitet
English: The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4+ T-lymphocytes.
Danish: Den antivirale aktivitet af tenofoviralafenamid mod isolater af hiv 1 undertype B fra laboratoriet og klinikken blev vurderet i lymfoblastoide cellelinjer, PBMC'er, primære monocyt-/makrofage celler og
English: The EC50 values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from 0.10 to 12.0 nM) and activity against HIV-2 (EC50 values ranged from 0.91 to 2.63 nM).
Danish: Tenofoviralafenamid viste antiviral aktivitet i cellekultur mod alle hiv 1-grupperne (M, N og O), herunder undertype A, B, C, D, E, F og G (EC50-værdier var i intervallet fra 0,10 til 12,0 nM) og viste stammespecifik aktivitet mod hiv 2 (EC50-værdier var i intervallet fra 0,91 til 2,63 nM).
English: Tenofovir alafenamide
Danish: Tenofoviralafenamid
English: How to take Biktarvy
Danish: Sådan skal De tage Biktarvy
English: Co-administration may decrease bictegravir plasma concentrations.
Danish: Samtidig administration kan reducere plasmakoncentrationen af bictegravir.
English: This is because some of the active substances in this medicine pass into human breast milk.
Danish: De må ikke amme, mens De er i behandling med Biktarvy, fordi nogle af de aktive stoffer i denne medicin udskilles i mælken hos mennesker.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Danish: Autoimmunsygdomme (som Graves sygdom og autoimmun hepatitis) er også rapporteret i tilfælde af immunreaktivering.
English: Co-administration with St. John's wort is contraindicated, due to the effect of St. John's wort on the bictegravir component of Biktarvy.
Danish: Samtidig administration med perikon er kontraindiceret på grund af perikons virkning på indholdsstoffet bictegravir i Biktarvy.
English: hyperbilirubinaemia Skin and subcutaneous tissue disorders Uncommon:
Danish: Hud og subkutane væv Ikke almindelig:
English: Tenofovir alafenamide:
Danish: Tenofoviralafenamid:
English: In treatment-naïve (Studies GS-US-380-1489 and GS-US-380-1490) and virologically-suppressed patients (Studies GS-US-380-1844 and GS-US-380-1878), no patient receiving Biktarvy had HIV-1 with treatment-emergent genotypic or phenotypic resistance to bictegravir, emtricitabine, or tenofovir alafenamide in the final resistance analysis population (n = 10) with HIV-1 RNA ≥ 200 copies/mL at the time of confirmed virologic failure, Week 48, Week 96 (treatment naïve studies only) or early study drug discontinuation.
Danish: hiv 1 med fremkomst af genotypisk eller fænotypisk resistens over for bictegravir, emtricitabin eller tenofoviralafenamid under behandlingen i den endelige resistensanalysepopulation (n = 10 med hiv 1RNA ≥ 200 kopier/ml på tidspunktet for bekræftet virologisk svigt, uge 48, uge 96 (kun behandlingsnaive studier) eller tidlig seponering af studielægemidlet.
English: Co-administration of rifampicin may decrease tenofovir alafenamide plasma concentrations.
Danish: Samtidig administration af rifampicin kan reducere plasmakoncentrationen af tenofoviralafenamid.
English: • If you notice 18 hours or more after the time you usually take Biktarvy, then do not take the missed dose.
Danish: • Hvis De kommer i tanker om det 18 timer eller længere efter det tidspunkt, De normalt tager
English: Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple dose mean (CV%) pharmacokinetic parameters of emtricitabine were Cmax = 2.13 µg/mL (34.7%), AUCtau = 12.3 µg•h/mL (29.2%), and Ctrough = 0.096 µg/mL (37.4%).
Danish: Cmax = 2,13 µg/ml (34,7 %), AUCtau = 12,3 µg•t/ml (29,2 %) og Ctrough = 0,096 µg/ml (37,4 %).
English: Co-administration of rifabutin may decrease tenofovir alafenamide plasma concentrations.
Danish: Samtidig administration af rifabutin kan reducere plasmakoncentrationen af tenofoviralafenamid.
English: (-5.6% to
Danish: til 0,6 %)
English: Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849
Danish: Tlf: + 46 (0) 8 5057 1849
English: Tenofovir alafenamide: AUC: ↔
Danish: Tenofoviralafenamid: AUC: ↔
English: Co-administration of rifapentine may decrease bictegravir and tenofovir alafenamide plasma concentrations.
Danish: Samtidig administration af rifapentin kan reducere plasmakoncentrationen af bictegravir og tenofoviralafenamid.
English: Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple dose mean (CV%) pharmacokinetic parameters of bictegravir were Cmax = 6.15 µg/mL (22.9%), AUCtau = 102 µg•h/mL (26.9%), and Ctrough = 2.61 µg/mL (35.2%).
Danish: Cmax = 6,15 µg/ml (22,9 %), AUCtau = 102 µg•t/ml (26,9 %) og Ctrough = 2,61 µg/ml (35,2 %).
English: Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80% of an oral dose.
Danish: Således metaboliseres > 80 % af en oral dosis.
English: HERBAL PRODUCTS St. John's wort (Hypericum perforatum) (Induction of CYP3A, UGT1A1, and P-gp)
Danish: Bictegravir1 (Induktion af CYP3A, UGT1A1, og P-gp)
English: • joint pain (arthralgia)
Danish: • ledsmerter (artralgi)
English: Co-administration may decrease bictegravir and tenofovir alafenamide plasma concentrations.
Danish: Samtidig administration kan reducere plasmakoncentrationen af bictegravir og tenofoviralafenamid.
English: What Biktarvy is and what it is used for What you need to know before you take Biktarvy How to take Biktarvy
Danish: Det skal De vide, før De begynder at tage Biktarvy Sådan skal De tage Biktarvy Bivirkninger
English: Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1849
Danish: Puh/Tel: + 46 (0) 8 5057 1849
English: Do not breast-feed during treatment with Biktarvy.
Danish: Biktarvy må derfor ikke anvendes under amning.
English: The mean baseline plasma HIV-1 RNA was 4.4 log10 copies/mL (range 1.3-6.6).
Danish: Forekomsten af forskellige undertyper var sammenlignelig på tværs af alle tre behandlingsgrupper, med undertype B som dominerende i begge grupper; 11 % var ikke undertype B. Gennemsnitligt hiv 1-rna i plasma ved baseline var 4,4 log10-kopier/ml (interval 1,3-6,6).
English: Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700
Danish: Tel: + 44 (0) 8000 113 700
English: Gilead Sciences Sweden AB Sími: + 46 (0) 8 5057 1849
Danish: Sími: + 46 (0) 8 5057 1849
English: Sofosbuvir metabolite GS-331007: AUC: ↔
Danish: GS-331007:
English: The prevalence of different HIV-1 subtypes was comparable between treatment groups, with subtype B predominant in both groups; 5% were non-B subtypes.
Danish: Forekomsten af forskellige hiv 1-undertyper var sammenlignelig i behandlingsgrupperne, med undertype B som dominerende i begge grupper; 5 % var ikke undertype B. Det gennemsnitlige CD4+ celletal ved baseline var 723 celler/mm3 (interval 124-2444).
English: Rifabutin (300 mg once daily), Bictegravir1
Danish: Rifabutin (300 mg én gang dagligt),
English: Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849
Danish: Tel: + 46 (0) 8 5057 1849
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration
Danish: MF (EU)-nummer
English: Karvea was used for two years or more.
Danish: Karvea blev anvendt i to år eller mere.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Karvea on 27 August 1997.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Karvea den 27. august 1997.
English: This is a summary of the European public assessment report (EPAR) for Karvea.
Danish: Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Karvea.
English: The full EPAR for Karvea can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Karvea findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The usual recommended dose of Karvea is 150 mg once a day.
Danish: Den normalt anbefalede dosis af Karvea er 150 mg en gang dagligt.
English: Other information about Karvea
Danish: Andre oplysninger om Karvea:
English: Karvea is a medicine that contains the active substance irbesartan.
Danish: Karvea er et lægemiddel, der indeholder det aktive stof irbesartan.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Karvea.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Karvea.
English: What is the risk associated with Karvea?
Danish: Hvilken risiko er der forbundet med Karvea?
English: For more information about treatment with Karvea, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Karvea, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: The CHMP decided that Karvea's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: CHMP besluttede, at fordelene ved Karvea opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
English: Why has Karvea been approved?
Danish: Hvorfor blev Karvea godkendt?
English: Karvea was originally studied in 11 trials for its effects on blood pressure.
Danish: Karvea var oprindelig genstand for 11 undersøgelser af dets virkning på blodtrykket.
English: The active substance in Karvea, irbesartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Danish: Det aktive stof i Karvea, irbesartan, er en "angiotensin II-receptorantagonist", hvilket betyder, at det blokerer virkningen af et hormon i kroppen kaldet angiotensin II.
English: Karvea was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients.
Danish: Karvea blev sammenlignet med placebo (en uvirksom behandling) hos 712 patienter og med andre lægemidler mod forhøjet blodtryk (atenolol, enalapril eller amlodipin) hos 823 patienter.
English: In this study, Karvea was compared with placebo and with amlodipine.
Danish: I denne undersøgelse blev Karvea sammenlignet med placebo og amlodipin.
English: When used with hydrochlorothiazide, the effects of the two medicines were additive.
Danish: Når Karvea blev anvendt i kombination med hydrochlorothiazid, var virkningerne af de to lægemidler additive.
English: Karvea must not be used in people who are hypersensitive (allergic) to irbesartan or any of the other ingredients.
Danish: Karvea må ikke anvendes til personer, som er overfølsomme (allergiske) over for irbesartan eller andre af indholdsstofferne.
English: Karvea in combination with aliskirencontaining medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Danish: Karvea i kombination med lægemidler, der indeholder aliskiren (som anvendes til behandling af essentiel hypertension), må ikke anvendes til patienter med diabetes eller moderat eller alvorlig nyresygdom.
English: Karvea is used in adults who have essential hypertension (high blood pressure).
Danish: Karvea anvendes til voksne med essentiel hypertension (forhøjet blodtryk).
English: Karvea is also used to treat kidney disease in adults with hypertension and type 2 diabetes (non-insulin-dependent diabetes).
Danish: Karvea anvendes desuden til behandling af nyresygdom hos voksne med hypertension og type 2-diabetes (ikke-insulinafhængig diabetes).
English: The most common side effect with Karvea (seen in more than 1 patient in 10) is hyperkalaemia (high blood potassium levels).
Danish: Den hyppigste bivirkning ved Karvea (som ses hos flere end 1 ud af 10 patienter) er hyperkalæmi (forhøjet kaliumindhold i blodet).
English: The second study looked at whether Karvea increased the time taken until the patients' blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
Danish: Den anden undersøgelse så på, hvorvidt Karvea forlænger den tid, der går, inden patienterne oplever en fordobling af indholdet af blodkreatinin (en markør for nyresygdom), inden de får behov for en nyretransplantation eller dialyse, eller inden de dør.
English: What is Karvea?
Danish: Hvad er Karvea?
English: For the full list of all side effects reported with Karvea, see the Package Leaflet.
Danish: Den fuldstændige liste over de indberettede bivirkninger ved Karvea fremgår af indlægssedlen.
English: For the treatment of kidney disease, Karvea was studied in two large studies involving a total of 2,326 patients with type 2 diabetes.
Danish: Karvea var desuden genstand for to store undersøgelser vedrørende behandling af nyresygdom hos 2 326 patienter med type 2-diabetes.
English: In the first kidney disease study, Karvea was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion.
Danish: I den første undersøgelse vedrørende nyresygdom var Karvea mere effektivt end placebo til at reducere risikoen for at udvikle nyreskader, hvilket blev målt ved proteinudskillelsen.
English: In the second kidney disease study, Karvea reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant, or death during the study by 20% in comparison with placebo.
Danish: I den anden undersøgelse vedrørende nyresygdom reducerede Karvea i løbet af undersøgelsen den relative risiko for en fordobling af indholdet af kreatinin i blodet, behovet for en nyretransplantation eller risikoen for dødsfald med 20 % sammenlignet med placebo.
English: In the blood pressure studies, Karvea was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Danish: I undersøgelserne af virkningen på blodtrykket var Karvea mere effektivt end placebo til at nedsætte det diastoliske blodtryk, og virkningerne af Karvea svarede til virkningerne af de andre lægemidler mod forhøjet blodtryk.
English: In patients with hypertension and type 2 diabetes, Karvea is added to some other treatments for hypertension.
Danish: Til patienter med forhøjet blodtryk og type 2-diabetes anvendes Karvea som tillægsbehandling til visse andre behandlinger af forhøjet blodtryk.
English: How has Karvea been studied?
Danish: Hvordan blev Karvea undersøgt?
English: What benefit has Karvea shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Karvea?
English: What is Karvea used for?
Danish: Hvad anvendes Karvea til?
English: How does Karvea work?
Danish: Hvordan virker Karvea?
English: How is Karvea used?
Danish: Hvordan anvendes Karvea?
English: If you suddenly notice:
Danish: Hvis du pludselig bemærker:
English: The applicant should submit yearly interim reports.
Danish: Ansøgeren indsender årlige interimsrapporter.
English: Date of first authorisation: 08/01/2013
Danish: Dato for første markedsføringstilladelse: 08/01/2013
English: There are no data from the use in pregnant women.
Danish: Der foreligger ingen data om anvendelse hos gravide kvinder.
English: Monitoring during treatment
Danish: Overvågning under behandlingen
English: You will receive KRYSTEXXA every 2 weeks.
Danish: Du vil få KRYSTEXXA hver 2. uge.
English: • CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Danish: • BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE EN SIKKER OG VIRKNINGSFULD ANVENDELSE AF LÆGEMIDLET
English: Availability of resuscitation equipment must be ensured.
Danish: Genoplivningsudstyr skal være til rådighed.
English: Delayed-type hypersensitivity reactions have also been reported.
Danish: Forsinkede typer hypersensitivitetsreaktioner er også blevet rapporteret.
English: The data for long-term treatment from controlled clinical studies are limited.
Danish: Data vedrørende langtidsbehandling i kontrollerede kliniske undersøgelser er begrænsede.
English: M0402: EU Pegloticase post-marketing Observational Study
Danish: M0402: EU-observationsundersøgelse for pegloticase efter markedsføring
English: The potential clinical relevance of these findings is currently unknown; however no adverse effects were associated with the presence of vacuoles.
Danish: Den eventuelle kliniske relevans af disse resultater kendes på nuværende tidspunkt ikke, men der var ingen negative virkninger forbundet med tilstedeværelsen af vakuoler.
English: Commercial House, Millbank Business Park, Lower Lucan Road, Lucan, Co. Dublin Ireland
Danish: Commercial House, Millbank Business Park, Lower Lucan Road, Lucan, Co. Dublin Irland
English: Take these medicines as directed by your doctor.
Danish: Brug disse lægemidler efter din læges anvisninger.
English: No overall differences in safety or efficacy were observed between older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Danish: Overordnet var der ingen forskel i sikkerhed eller virkning mellem ældre og yngre patienter, men det kan ikke udelukkes, at nogle ældre patienter er mere følsomme.
English: Close monitoring is required during the infusion and for at least 2 hours after the end of the infusion.
Danish: Der kræves tæt overvågning under infusionen og mindst 2 time efter afslutning af infusionen.
English: Therefore, this medicine is not recommended in this age group.
Danish: Lægemidlet anbefales derfor ikke til denne patientgruppe.
English: Your doctor may also ask you to wait after your treatment to be sure that you do not have an infusion-related reaction.
Danish: Lægen vil muligvis også bede dig vente efter behandlingen for at sikre, at du ikke har en infusionsrelateret reaktion.
English: Therefore, KRYSTEXXA should not be used during breast-feeding unless the clear benefit to the mother can overcome the unknown risk to the newborn/infant.
Danish: Derfor bør KRYSTEXXA ikke anvendes under amning, medmindre fordelen for moderen klart opvejer den ukendte risiko for den nyfødte/spædbarnet.
English: In addition, a further amendment regarding the extension of the time of observation following the end of infusion from 1 hour to 2 hours as a precautionary measure has been included along with a statement that delayed-type hypersensitivity reactions have also been reported.
Danish: Desuden er der også blevet inkluderet en ændring angående den forlængede observationsperiode efter infusionen er færdig, fra 1 time til 2 timer som en forsigtighedsregel, sammen med en erklæring om, at der også er blevet rapporteret forsinkede typer hypersensitivitetsreaktioner.
English: Although the 4-week regimen also demonstrated efficacy for the primary endpoint, this regimen was associated with increased frequency of infusion reactions.
Danish: 4-ugers regimet havde også virkning på det primære endepunkt, men var forbundet med øget hyppighed af infusionsreaktioner.
English: This medicine will be stored in a healthcare facility where it is administered.
Danish: Dette lægemiddel vil blive opbevaret på det behandlingscenter, hvor det skal gives.
English: • The active substance is pegloticase.
Danish: • Det aktive stof er pegloticase.
English: In the pregnant rat study there was no evidence of embryotoxicity or teratogenicity at 46 times the clinical exposure (AUC).
Danish: I undersøgelsen med drægtige rotter var der ingen tegn på embryotoksicitet eller teratogenicitet ved 46 gange den kliniske eksponering (AUC).
English: The CHMP agrees with the scientific conclusions made by the PRAC.
Danish: CHMP tilslutter sig PRAC's videnskabelige konklusioner
English: It is unknown whether the development of anti-PEG antibodies may reduce the efficacy of other PEGylated medicinal products.
Danish: Det vides ikke, om udvikling af anti-PEG-antistoffer kan nedsætte virkningen af andre PEGylerede lægemidler.
English: The recommended dose of KRYSTEXXA is 8 mg.
Danish: Den anbefalede dosis af KRYSTEXXA er 8 mg.
English: This dose is not adjusted for weight, age or kidney disease.
Danish: Denne dosis er ikke korrigeret for vægt, alder eller nyresygdom.
English: Non-clinical studies to evaluate the carcinogenic and mutagenic potential have not been performed.
Danish: Der er ikke udført ikke-kliniske undersøgelser til vurdering af det carcinogene og mutagene potentiale.
English: It is recommended to start this treatment 1 week before initiation of KRYSTEXXA and continue for at least 6 months, unless medically contraindicated or not tolerated.
Danish: Det anbefales at påbegynde denne behandling 1 uge før iværksættelse af behandlingen med KRYSTEXXA og fortsætte i mindst seks måneder, medmindre den er lægeligt kontraindiceret eller ikke tolereres.
English: • a rash, itching or hives tell your doctor or nurse IMMEDIATELY, since any of these may be signs of a serious allergic reaction.
Danish: • udslæt, kløe eller nældefeber skal du STRAKS sige det til lægen eller sygeplejersken, da ethvert af disse symptomer kan være tegn på en alvorlig allergisk reaktion.
English: The following convention has been used for classification of the adverse reactions reported in the Phase 3 clinical trials (see Table 1 below): very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Danish: Følgende konvention er anvendt til klassificering af de indberettede bivirkninger i fase 3-kliniske undersøgelser (se tabel 1 nedenfor): Meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1 000 til < 1/100), sjælden (≥ 1/10 000 til < 1/1 000), meget sjælden (< 1/10 000), ikke kendt (kan ikke beregnes af forhåndenværende data).
English: Number of Patients with CR (%)2
Danish: Antal patienter med fuldstændig remission ( %)2